March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merck & Co
(NYSE:MRK)
Intraday
$131.95
0.20
[0.15%]
After-Hours
$131.95
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$131.95
0.20
[0.15%]
At close: Mar 28
$131.95
0
[0.00%]
After Hours: 7:56PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Merck & Co Stock (NYSE:MRK)
Merck & Co Stock (NYSE: MRK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
Looking At Merck & Co's Recent Unusual Options Activity
Benzinga Insights
-
13 hours ago
Truist Securities Reiterates Buy on Merck & Co, Raises Price Target to $142
Benzinga Newsdesk
-
16 hours ago
Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept
Akanksha Bakshi
-
20 hours ago
The European Commission Approves Merck's Keytruda In Combination With Platinum-containing Chemotherapy As Neoadjuvant Treatment, Then Continued As Monotherapy As Adjuvant Treatment, For Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence
Benzinga Newsdesk
-
21 hours ago
Wednesday, March 27, 2024
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Surbhi Jain
-
1 day ago
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Vandana Singh
-
1 day ago
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
1 day ago
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target
Benzinga Newsdesk
-
1 day ago
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
Vandana Singh
-
1 day ago
Wells Fargo Maintains Equal-Weight on Merck & Co, Raises Price Target to $135
Benzinga Newsdesk
-
1 day ago
US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead
Shanthi Rexaline
-
1 day ago
Merck shares are trading higher after the company received FDA approval for Winrevair (sotatercept) for adults with pulmonary arterial hypertension.
Benzinga Newsdesk
-
1 day ago
Tuesday, March 26, 2024
FDA Approved Merck's Winrevair For Treatment Of Adults With Pulmonary Arterial Hypertension
Charles Gross
-
2 days ago
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Vandana Singh
-
2 days ago
Monday, March 25, 2024
Smart Money Is Betting Big In MRK Options
Benzinga Insights
-
3 days ago
Thursday, March 21, 2024
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Vandana Singh
-
Mar 21, 2024, 2:46PM
Merck's Phase 3 KEYLYNK-006 Trial Of Keytruda In Combination With Maintenance Lynparza Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-free Survival As First-line Treatment Of Metastatic Nonsquamous Non-small Cell Lung Cancer
Benzinga Newsdesk
-
Mar 21, 2024, 6:47AM
Wednesday, March 20, 2024
Looking At Merck & Co's Recent Unusual Options Activity
Benzinga Insights
-
Mar 20, 2024, 2:31PM
Tuesday, March 19, 2024
Merck & Co Inc Files For Debt Shelf; Size Not Disclosed
Benzinga Newsdesk
-
Mar 19, 2024, 5:02PM
Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine
Vandana Singh
-
Mar 19, 2024, 2:42PM
Merck Announces Data On V116, An Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults, Demonstrated Immune Responses In Adults
Benzinga Newsdesk
-
Mar 19, 2024, 9:01AM
Monday, March 18, 2024
U.S. CDC Issues Health Alert Network Health Advisory On Increase In Global And Domestic Measles Cases And Outbreaks; Says Ensure Children In The United States And Those Traveling Internationally 6 Months And Older Are Current On MMR Vaccination
Benzinga Newsdesk
-
Mar 18, 2024, 1:54PM
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Vandana Singh
-
Mar 18, 2024, 10:21AM
Friday, March 15, 2024
Newly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival
Vandana Singh
-
Mar 15, 2024, 3:17PM
Merck Announced That The Phase 3 KEYNOTE-A18 Trial Of Keytruda In Combination With Chemoradiotherapy Met Its Primary Endpoint Of Overall Survival For Newly Diagnosed Patients With High-risk Locally Advanced Cervical Cancer
Benzinga Newsdesk
-
Mar 15, 2024, 6:47AM
Thursday, March 14, 2024
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Vandana Singh
-
Mar 14, 2024, 4:03PM
Wednesday, March 13, 2024
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
Benzinga Insights
-
Mar 13, 2024, 12:00PM
Merck Plans To Conduct Clinical Trials Of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine And Single-Dose Regimen For GARDASIL®9
Benzinga Newsdesk
-
Mar 13, 2024, 3:09AM
Tuesday, March 12, 2024
Ideaya Biosciences Has Entered Into A Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Its IDEE161 In Combination With Keytruda (Pembrolizumab) For Endometrial Cancer, In A Phase 1 Trial
Benzinga Newsdesk
-
Mar 12, 2024, 6:11AM
Monday, March 11, 2024
What's Going On With Moderna Stock On Monday?
Vandana Singh
-
Mar 11, 2024, 2:08PM
Societe Generale Downgrades Merck & Co to Sell, Announces $104 Price Target
Benzinga Newsdesk
-
Mar 11, 2024, 1:34PM
"Moderna Rises On New Skin Cancer Treatment Trial With Merck, Analysts Say" - Reuters
Benzinga Newsdesk
-
Mar 11, 2024, 11:59AM
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target
Benzinga Newsdesk
-
Mar 11, 2024, 9:20AM
Thursday, March 07, 2024
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Vandana Singh
-
Mar 7, 2024, 9:15AM
Wednesday, March 06, 2024
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Vandana Singh
-
Mar 6, 2024, 4:30PM
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Vandana Singh
-
Mar 6, 2024, 4:21PM
Gilead and Merck Announce Phase 2 Data Showing An Investigational Oral Once-Weekly Combination Regimen Of Islatravir And Lenacapavir Maintained Viral Suppression At Week 24
Benzinga Newsdesk
-
Mar 6, 2024, 10:26AM
Tuesday, March 05, 2024
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
Natan Ponieman
-
Mar 5, 2024, 4:45PM
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
Vandana Singh
-
Mar 5, 2024, 12:16PM
Friday, March 01, 2024
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Chris Katje
-
Mar 1, 2024, 10:39AM
Thursday, February 29, 2024
Critical Insights From Merck & Co Analyst Ratings: What You Need To Know
Benzinga Insights
-
Feb 29, 2024, 2:01PM
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target
Benzinga Newsdesk
-
Feb 29, 2024, 1:45PM
Wednesday, February 28, 2024
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
Benzinga Insights
-
Feb 28, 2024, 11:00AM
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
Upwallstreet
-
Feb 28, 2024, 10:54AM
Monday, February 26, 2024
Merck Said Along With AstraZeneca, Filed A Patent Infringement Lawsuit In The U.S. District Court For The District Of New Jersey Against Novartis Sandoz Unit
Charles Gross
-
Feb 26, 2024, 4:53PM
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
Vandana Singh
-
Feb 26, 2024, 1:15PM
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Feb 26, 2024, 12:35PM
Behind the Scenes of Merck & Co's Latest Options Trends
Benzinga Insights
-
Feb 26, 2024, 11:00AM
Friday, February 23, 2024
Merck Says It Received Positive EU CHMP Opinion For KEYTRUDA (Pembrolizumab) In Combination With Chemotherapy As Neoadjuvant Treatment, Then Continued As Monotherapy As Adjuvant Treatment, For Treatment Of Resectable NSCLC At High Risk Of Recurrence
Benzinga Newsdesk
-
Feb 23, 2024, 6:24AM
Thursday, February 22, 2024
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Upwallstreet
-
Feb 22, 2024, 12:21PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch